Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients.

Date publication

octobre 2019

Journal

Breast cancer research and treatment

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry , Pr PIVOT Xavier , Pr VELTEN Michel

Tous les auteurs :
Herrscher H, Velten M, Leblanc J, Kalish-Weindling M, Fischbach C, Exinger D, Pivot X, Petit T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31612291

Résumé

We report the results of a retrospective analysis of the fulvestrant and palbociclib combination within a temporary authorization of use (TAU) program in 77 heavily pretreated patients with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer.

Mots clés

Advanced breast cancer, CDK 4/6 inhibitors, Endocrine therapy, Fulvestrant, Palbociclib

Référence

Breast Cancer Res. Treat.. 2019 Oct 14;: